Zealand Pharma A/S (OTCMKTS:ZLDPF) Short Interest Up 39.7% in December

Zealand Pharma A/S (OTCMKTS:ZLDPF) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,166,300 shares, a growth of 39.7% from the December 15th total of 835,100 shares. Based on an average daily volume of 2,100 shares, the short-interest ratio is currently 555.4 days.

Zealand Pharma A/S Trading Down 0.4 %

OTCMKTS:ZLDPF opened at $97.10 on Wednesday. Zealand Pharma A/S has a one year low of $64.10 and a one year high of $141.74. The business has a fifty day moving average price of $104.95 and a 200-day moving average price of $119.05. The firm has a market capitalization of $5.00 billion, a price-to-earnings ratio of -39.96 and a beta of 0.89. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49.

Wall Street Analyst Weigh In

Separately, JPMorgan Chase & Co. assumed coverage on shares of Zealand Pharma A/S in a research report on Friday, November 8th. They set an “overweight” rating for the company.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.